The DNA testing company, which has 10 million customers, misses nearly 90 percent of people with risky BRCA mutations. It says the criticism is overblown.
Source:
https://www.nytimes.com/2019/04/16/health/23andme-brca-gene-testing.html?partner=rss&emc=rss